1 1 9 0 VOLUME 21 | NUMBER 10 | OCTOBER 2015 nAture medicine B cell non-Hodgkin lymphomas (B-NHL) represent a heterogeneous group of malignancies that originate mostly from B cells in the GC and are driven by distinct genetic lesions disrupting key oncogenic pathways 1,2 . Recent exome and transcriptome sequencing efforts have revealed recurrent mutations in epigenetic modifiers, including methyltransferases, acetyltransferases and histone proteins themselves, suggesting that perturbations of epigenetic mechanisms play critical roles in lymphomagenesis [3] [4] [5] [6] [7] [8] . Among these genes, KMT2D (also known as MLL2, ALR or MLL4) is the one most frequently mutated, being found in ~30% of de novo DLBCLs (including both molecular subtypes: germinal center B cell-like (GCB) DLBCL and activated B cell-like (ABC) DLBCL) 9 and ~90% of FLs 3, [5] [6] [7] [8] 10, 11 , which together account for >70% of all B-NHL diagnoses. Moreover, recent studies investigating the history of clonal evolution during histologic transformation of FL to DLBCL (also called transformed FL, tFL) revealed that mutations in KMT2D represent early events that are introduced in a common ancestor before divergent evolution to FL or tFL through the acquisition of additional genetic lesions and final clonal expansion in the GC 7, 8, 10, 11 . KMT2D encodes a conserved member of the SET1 family of histone lysine methyltransferases (KMTs), which catalyze the methylation of lysine 4 on histone H3 (H3K4)-a modification associated with transcriptionally active chromatin [12] [13] [14] . The enzymatic function of KMT2D depends on a cluster of conserved C-terminal domains, including a plant homeodomain (PHD), two phenylalanine and tyrosine (FY)-rich motifs (FY-rich, N-terminal (FYRN) and FY-rich, C-terminal (FYRC)) and a catalytic Su(var)3-9, Enhancer-of-zeste, Trithorax (SET) domain. Whereas a single multisubunit complex known as 'Complex of Proteins Associated with Set 1' (COMPASS) is responsible for all methylation of H3K4 in yeast [15] [16] [17] [18] , six different KMTs have been identified in higher eukaryotes, which fall into three subgroups on the basis of homologies in protein sequence and subunit composition: SET1A-SET1B, MLL1-MLL4 (KMT2A-KMT2B) and MLL3-MLL2 (KMT2C-KMT2D) [12] [13] [14] . These findings suggest that the three KMT complexes exert nonoverlapping, highly specialized functions by regulating the transcription of discrete subsets of genes. In particular, KMT2C-KMT2D localize and function as major histone H3K4 mono-and dimethyltransferases at enhancers in mammalian cells [19] [20] [21] [22] [23] . Consistent with the involvement of KMT2D in critical cellular functions, germline homozygous deletion of this gene in mice results in embryonic lethality 21 .
KMT2D protein, but their functional consequences remain unexplored. In 30-75% of the mutated tumor samples KMT2D genetic lesions are biallelically distributed, whereas in the remainder of the samples, one intact KMT2D allele is retained, suggesting that this gene may function as a haploinsufficient tumor suppressor in at least a subset of cases. Indeed, monoallelic truncating mutations of KMT2D are considered to be the causative event in a rare congenital disease known as Kabuki syndrome, an observation that offers direct proof for the dosedependent pathogenic effect of this enzyme in other tissues 24 .
A few studies have investigated the biochemical function of KMT2D in mammals (in mouse adipogenesis and myogenesis or in human colon cancer cell lines and haematopoietic cells, among others) [20] [21] [22] 25, 26 ; however, little is known about the general role of this protein and its mutant alleles in B cells and the mechanisms by which KMT2D mutations contribute to lymphoma development. Here we performed a comprehensive characterization of the mechanisms (genetic and epigenetic) that disrupt KMT2D function in B-NHL and explored its role in normal B cell development and lymphomagenesis in mice.
RESULTS

Genetic and epigenetic inactivation of KMT2D in DLBCL
We first characterized the mRNA expression pattern of KMT2D in healthy mouse and human mature B cell subpopulations. Consistent with the ubiquitous nature of other MLL family members, KMT2D transcripts were detected in purified naive, GC and memory B cells (Supplementary Fig. 1 ). Accordingly, coimmunofluorescence analysis of KMT2D and the GC-specific marker BCL6 in reactive human tonsils revealed positive KMT2D staining in the nuclei of all mature B cell compartments, including the GC (Fig. 1a) .
We next used immunoblot analysis and immunohistochemistry (IHC) to measure the abundance of KMT2D in 123 DLBCL samples (26 cell lines and 97 primary biopsies) that are representative of various KMT2D genomic configurations (wild-type alleles, biallelic truncating mutations and heterozygous truncating or missense mutations). We used an antibody that specifically recognizes an epitope in the C-terminal portion of the KMT2D protein, thus allowing for identification of the full-length polypeptide (see Supplementary  Fig. 2 for antibody characterization). As expected, we did not detect expression of the intact protein in all of the samples carrying biallelic truncating mutations that eliminated this epitope (Fig. 1b,c) . Moreover, immunoblot analysis using antibodies directed against the N-terminal half of KMT2D failed to reveal any signal corresponding to the truncated proteins in all seven cell lines tested ( Supplementary  Fig. 2f,g ), even after treatment with the proteasomal inhibitor MG132 (data not shown), despite expression of the mutant cDNA, suggesting that mechanisms other than proteosomal degradation are responsible for the lack of expression of the truncated proteins in these cells.
We then investigated whether the residual wild-type allele is still expressed in samples carrying KMT2D monoallelic (truncating) mutations. Whereas the KMT2D protein was barely detectable in 2 of 18 samples analyzed, the remaining cell line and all 15 biopsies stained positive for the full-length protein (Fig. 1b-d) . Of note, markedly reduced amounts of protein, or none, were also observed in 9 of the 77 (11.7%) samples lacking KMT2D genetic lesions ( Fig. 1b-d) , suggesting that additional epigenetic mechanisms may interfere with KMT2D protein expression in a small subset of tumors. Overall, ~45% of DLBCLs lack KMT2D either completely, due to biallelic genetic lesions and loss of protein expression (20% of cases), or partially, due to monoallelic mutations (25% of cases) (Fig. 1e) .
Missense mutations impair KMT2D methyltransferase activity Most KMT2D mutations are postulated to generate truncated proteins that are functionally defective due to the loss of the catalytic SET domain. However, ~7.3% of de novo DLBCLs and 23% of tFLs in our data set harbor missense mutations that affect various residues along the KMT2D protein (18 of 89 mutational events, 20.2%; and 33 of 182 events from published DLBCL and tFL genomic studies, 18.1%) ( Fig. 2a and Supplementary Fig. 3 ) 3, [5] [6] [7] [8] . To test the functional impact of KMT2D missense mutations, we generated hemagglutinin (HA)-tagged versions of 16 lymphomaderived mutant alleles ( Fig. 2b and Supplementary Fig. 4a ) and measured their basal expression upon transient transfection in 293T cells. With one exception (S5404F), all of the alleles tested produced similar amounts of both mRNA and protein as those from the wild-type allele or from three germline variants that were included as controls, indicating that missense mutations generally do not interfere with the stability of the KMT2D protein (Supplementary Fig. 4b) .
We then measured the ability of these proteins to catalyze methylation of H3K4 in vitro using an artificial H3 peptide substrate or purified nucleosomal histones 27 . In both assays, each of the nine mutations that were present in the C-terminal domains significantly impaired enzymatic activity as compared to that of the wild-type protein (Fig. 2c,d ). In particular, immunoblot analysis of nucleosomal histones using specific antibodies to distinct methylation states revealed a substantial reduction in H3K4 monomethylation (H3K4me1), dimethylation (H3K4me2) and trimethylation (H3K4me3) (Fig. 2d) . In contrast, the enzymatic activities of seven polypeptides carrying mutations in the N-terminal half of the protein were only modestly affected or indistinguishable from those of either the wild-type control or the germline mutants (Fig. 2b-d) . These amino acid changes *** *** *** *** *** *** ** ** ** ** ** ** ** D5257V  R5432W  L5056P  C5092S  C5092Y  N5437S  E4712*  G5467D  R5303H  V4799M   R5303H  V4799M  R5027L  D5257V  R5432W  L5056P  C5092S  C5092Y  N5437S  E4712*  G5467D   C5092S  C5092Y  D5257V  R5432W  N5437S  G5467D In-frame deletion pCMV- HA-MLL2   T1506S  S1065T  P1104T  D1121H  R2095S   WT  C2468T  R4659P  pCMV-HA   T1506S  S1065T  P1104T  D1121H  R2095S  C2468T  R4659P (Fig. 2e) . Moreover, all three epigenetic marks were reduced in four DLBCL cell lines that lack KMT2D protein expression due to the presence of biallelic truncating mutations; the degree of reduction was variable depending on culture conditions but was consistently significant as compared to that of three wild-type cell lines (P < 0.001) (Fig. 2f for representative results). Consistent with these findings, over 95% of KMT2D-bound chromatin in GC B cells was decorated by H3K4me1 (1,517/4,153 peaks, 36%) and/or H3K4me3 (2,578/4,153 peaks, 62%) (Fig. 2g,h ). Collectively our data indicate that, despite being present in only one of the six mammalian COMPASS-like complexes, KMT2D functions as a nonredundant methyltransferase that controls, either directly or indirectly, the methylation state of a large number of regions in the mature B cell compartment.
Early loss of Kmt2d affects follicular B cell development Since the stage of hematopoietic differentiation in which KMT2D lesions occur is unknown, we generated mouse models in which Kmt2d could be conditionally deleted at distinct stages of B cell differentiation by crossing mice bearing a floxed Kmt2d allele 21 with mice expressing the Cre recombinase specifically either in GC B cells (Kmt2d fl/fl Cγ1-Cre) 28 or in B cell progenitors (Kmt2d fl/fl CD19-Cre) 29 . Animals were analyzed before and 10 d after immunization with sheep red blood cells (SRBC), a T cell-dependent antigen that elicits robust GC responses and, in the case of the Cγ1-Cre model, is required to induce the expression of Cre.
We did not find significant differences in the distribution of bone marrow (BM) B cell subpopulations, splenic follicular (FO) B cells and marginal zone (MZ) B cells between unimmunized Kmt2d fl/fl CD19-Cre and littermate Kmt2d fl/+ and Kmt2d +/+ controls ( Supplementary  Fig. 5 ). The percentages and absolute numbers of pro-, pre-and immature B cells in the BM were comparable even after SRBC immunization ( Supplementary Fig. 6a,b) . However, immunized Kmt2d fl/fl CD19-Cre mice displayed a significant (P < 0.05) reduction in splenic and lymph node B220 + cells (Supplementary Fig. 6c,d ) as well as in the fraction of mature B cells recirculating in the BM ( Supplementary  Fig. 6b ). Since mature B lymphocytes derive sequentially from transitional type 1 (T1) and type 2 (T2) precursors 30 , we then examined the distribution of various B cell subsets in the spleens of immunized mice. While no significant differences were noted in the absolute numbers of transitional 31 and MZ B cells, FO B cells were markedly less numerous in the absence of Kmt2d (Supplementary Fig. 6c,d) , suggesting that its function is more important in the development and maintenance of this population. Since these defects were absent or modest in unimmunized mice, we conclude that these effects are not due to a block in differentiation but may reflect impaired homeostasis of FO B cells. Fig. 7a-d) . Accordingly, Kmt2d fl/fl Cγ1-Cre and Kmt2d fl/+ Cγ1-Cre mice were indistinguishable from wild-type controls in the size and number of GCs, in the numbers of IgG1 + B cells and plasma cells and in the total IgG1 serum levels ( Supplementary Fig. 7e-g ). Thus, GC development occurs normally when Kmt2d is deleted as early as 4 d after the initiation of the GC reaction 28 .
Early deletion of
In contrast, SRBC-immunized Kmt2d fl/fl CD19-Cre mice displayed up to a three-fold expansion in the percentage and absolute number of GC B cells, which was paralleled by a significant increase in mean GC size, overall GC area and, at 6 months of age, total number of GCs in the spleen (Fig. 3) , along with augmented numbers of surface IgG1-expressing cells (Supplementary Fig. 8 ). Analogous results were obtained when animals were challenged with the clonally restricted T cell-dependent antigen NP-KLH (4-hydroxy-3-nitrophenylacetyl hapten conjugated to keyhole limpet hemocyanin) ( Supplementary  Fig. 9a-d Supplementary Table 2 for a complete list); colored circles denote the enrichment P value in the two models (the smaller the P value, the larger the size and the color intensity Fig. 9e ). Accordingly, a smaller proportion of GC B cells harbored the W33L substitution in the immunoglobulin variable heavy-chain region 186.2, a well-established readout of high affinity for the NP hapten ( Supplementary Fig. 9f ) 32 . Together with the observation of otherwise normal somatic hypermutation ( Supplementary Fig. 9g,h ), these data suggest a modest impairment of Kmt2d-deficient cells in affinity maturation, which in turn could reflect inefficient cell selection. The observation that loss of Kmt2d early during B cell development leads to enhanced GC responses was notable when considering that B220 + cells, and specifically the number of FO B cells (which represents the population that gives rise to GC B cells), were markedly reduced in these animals ( Supplementary Fig. 6d ). An intermediate phenotype could also be appreciated in the GC responses of heterozygous mice (Fig. 3) , suggesting that Kmt2d dosage reduction has subtle pathogenic effects in this population.
Collectively these findings suggest a propensity of Kmt2d-deficient FO B cells to enter the GC reaction in response to antigenic stimuli and support a model whereby the early deletion of Kmt2d (before GC formation) may influence T cell-dependent responses by remodeling the epigenetic landscape of the precursor B cells.
Early loss of Kmt2d induces transcriptional changes in GC B cells
To understand the mechanisms underlying the differential effect of Kmt2d loss in early versus late B cell development, we contrasted the gene expression profiles (GEP) of GC B cells isolated from immunized Kmt2d fl/fl , Kmt2d fl/+ and Kmt2d +/+ animals in both the Cγ1-Cre and the CD19-Cre cohorts. We found that 221 genes were differentially expressed between Kmt2d-deficient and Kmt2d-proficient cells in the CD19-Cre background, whereas 60 genes were differentially expressed in the Cγ1-Cre compound mice (Student's t-test, false discovery rate (FDR) < 0.15, fold change (FC) ≥ 1.5), suggesting that the stage and/or timing of Kmt2d deletion influences the transcriptional changes occurring in the GC population ( Fig. 4a and Supplementary Table 1 ). However, cross-comparison of the signatures obtained in the two genetic backgrounds by an extended GSEA approach 33 revealed a significant (P < 0.001) overlap between the top differentially expressed genes and their relative ranking in the two models (Fig. 4b) . Thus the nature of the induced transcriptional changes was highly similar, independently of whether the ablation of Kmt2d occurred before or after GC initiation. Consistent with this observation, both Cγ1-Cre and CD19-Cre Kmt2d-deficient GC B cells showed enrichment in overlapping biological programs, the most notable of which were cell cycle regulation (e.g., Ccnd3, Ccnf and Cdk6) and apoptosis (e.g., upregulation of the anti-apoptotic genes Bcl2l1 and Bcl2 and downregulation of the pro-apoptotic genes Bmf and Dedd2) (Fig. 4c,d, Supplementary  Fig. 10a and Supplementary Table 2) .
Intersection of GEP data with KMT2D ChIP-seq data from human GC centroblasts revealed that only a minority of the downregulated genes (n = 142/1,028, 14%) were bound by KMT2D, even when using less stringent cutoffs (Supplementary Notes, Supplementary  Fig. 10b,c and Supplementary Table 3) . Thus, within the inherent limits of the cross-species comparison, the phenotypic changes imposed by Kmt2d deficiency are mostly indirect. Nonetheless, the set of predicted bona fide direct targets of KMT2D activity (i.e., the genes occupied by KMT2D at active promoters and/or enhancers and downregulated following Kmt2d deletion; see Online Methods) were significantly (P < 0.05) enriched in biological programs with key functions in B cell physiology and pathology, including B cell receptor activation and signaling, chemokine and cytokine signaling and lymphocyte migration [34] [35] [36] (Fig. 4e,f and Supplementary Table 3) . Taken together, our data indicate that the transcriptional signature imposed by Kmt2d loss is enriched in biological programs that favor proliferation and survival and that the loss of Kmt2d early on, before GC induction, facilitates the establishment and influences the magnitude of these transcriptional changes. Kmt2D loss confers a B cell-proliferative advantage On the basis of the above findings, we investigated whether loss of Kmt2d affects proliferation and cell cycle regulation. Because GC B cells cannot survive ex vivo due to the rapid inception of a proapoptotic program 37 , we first measured the proliferative capacity of B220 + cells that were isolated from the spleens of CD19-Cre and Cγ1-Cre mice and stimulated with CD40-specific antibody and IL4, which mimics the signals delivered in vivo to induce GC responses. By day 3 poststimulation, CD19-Cre Kmt2d-deficient cells (but not Cγ1-Cre Kmt2d-deficient cells; Supplementary Fig. 11 ) had undergone a significantly (P < 0.01) higher number of cell divisions and had generated greater numbers of viable cells, as compared to their heterozygous and wild-type littermates (Fig. 5a-c) . Accordingly, the proportion of cells residing in the S phase of the cell cycle was significantly augmented in Kmt2d-deficient mice (on average, 45% versus 35% in Kmt2d wild-type controls; P < 0.001; Fig. 5d,e) . The increased response to the stimulation with CD40-specific antibody and IL4 is unlikely to be due to an altered distribution of B cell subsets in the splenic B220 + population of Kmt2d-deficient mice, as the proportion of FO and MZ B cells in these mice under unimmunized conditions was similar to those in the wild-type controls ( Supplementary  Fig. 5 ). Analysis of DNA content in freshly purified GC B cells confirmed that a significantly larger number of cells were actively cycling in the Kmt2d-null mice (P < 0.01; Fig. 5f,g ). Conversely, we did not detect measurable changes in apoptosis under these conditions (data not shown). Taken together, these findings indicate that loss of Kmt2d provides a substantial proliferative advantage and suggest one possible mechanism by which tumor-associated inactivating mutations might contribute to tumor development.
Loss of Kmt2d cooperates with Bcl2 in lymphomagenesis
To examine whether KMT2D is a bona fide tumor suppressor gene in B cells, we investigated the impact of Kmt2d deficiency on lymphoma development in vivo, either as a single lesion or in cooperation with BCL2 deregulation, a genetically driven event that co-occurs with KMT2D mutations in nearly all affected FL and tFL cases and in ~36% of KMT2D-mutated DLBCL cases 3, 5, 8 . Toward this end, we crossed Kmt2d fl/fl Cγ1-Cre animals with VavP-Bcl2 transgenic mice, which develop FL preceded by GC hyperplasia in 37-50% of cases 38 , and monitored the resulting mice for tumor incidence and survival over a period of 18 months. We did not observe significant differences between Kmt2d fl/fl , Kmt2d fl/+ and Kmt2d +/+ Cγ1-Cre littermates, indicating that loss of Kmt2d in the GC is not sufficient to drive malignant transformation ( Fig. 6a and data not shown) . Kmt2d deletion also had no impact on the event-free survival of compound VavP-Bcl2 animals, all of which died by 13 months of age, probably because of the severe glomerulonephritis and autoimmune diseases that develop in this strain at nearly 100% penetrance, as previously reported 38, 39 .
However, histological analysis of the lymphoid organs revealed that, compared to VavP-Bcl2 littermate controls, a significantly higher proportion of Kmt2d fl/fl Cγ1-Cre × VavP-Bcl2 mice had evolved to develop clonal B cell lymphoproliferative disorders that recapitulated the spectrum of phenotypes associated with the progression of FL to DLBCL: that is, early stages of FL (eFL), overt FL of various grades and DLBCL (overall, 22/28 (78.6%) Kmt2d fl/fl mice versus 15/24 (62.5%) Kmt2d fl/+ mice and 12/27 (44.4%) Kmt2d +/+ mice; P < 0.05; Fig. 6a,b) . These tumors were of GC B cell origin, as they stained positive for the pan-B cell markers B220 and Pax5, as well as for Bcl6 (Fig. 6b and data not shown) . Furthermore, Southern blot analysis of the immunoglobulin locus documented a clonal origin in 92% of the DLBCLs, 55% of the FLs and 23.5% of the eFLs tested (Fig. 6c,d) . The inability to detect clonal rearrangements in many of the latter can probably be explained by the limited representation of tumor cells in the biopsy (Fig. 6b; see the eFL panel); as such, the larger number of clonal lymphoproliferations observed in the Kmt2d-knockout mice might reflect a more advanced degree of tumor infiltration or aggressiveness. Most notably, 7 of 7 clonal tumors that were sequenced harbor somatically hypermutated immunoglobulin genes, providing unequivocal evidence of their derivation from a GC-experienced cell (Supplementary Table 4) . Together, these data suggest that loss of Kmt2d cooperates with Bcl2 deregulation npg to facilitate the development of GC B cell malignancies that recapitulate the features of human FL and DLBCL.
DISCUSSION
The first result of this study is the identification of two additional mechanisms by which KMT2D is inactivated in DLBCL and FL-missense mutations affecting its C-terminal cluster of SET domains and, in a small subset of cases, loss of protein expression, implicating epigenetic silencing. Thus, multiple modes of inactivation are responsible for defective KMT2D function in nearly 50% of cases of DLBCL and possibly in all cases of FL. We documented that in samples with monoallelic KMT2D mutations, which constitute up to two-thirds of affected DLBCL cases and ~45% of FL and tFL cases, the residual wild-type allele is always expressed and that conditional heterozygous deletion of Kmt2d leads to a GC phenotype intermediate between that of wild-type and knockout littermates. This suggests that dose reduction of KMT2D may also be pathogenic in the context of B cells, in a manner analogous to the haploinsufficient role of KMT2D in Kabuki syndrome 24 . The reason why a subset of tumors retain one copy of KMT2D is not known, but it may be related to the presence of unique combinations of genetic alterations in molecules with partly overlapping functions within the complex genomic landscape of DLBCL and tFL. One such candidate is the KMT2D paralog KMT2C-which was shown to have partial functional redundancy 21 and is also mutated in these diseases, albeit at lower frequencies [6] [7] [8] 40 . Although KMT2C mutations have not been functionally characterized and the number of individuals carrying these genetic aberrations is too low to assess statistical significance, these lesions seem more common in cases with monoallelic versus biallelic KMT2D lesions (5/42 versus 1/38 in our data set).
Both in vitro and in vivo, loss of KMT2D activity resulted in significant reduction of bulk H3K4 methylation, a highly conserved histone modification that regulates transcriptionally active promoters and enhancers [12] [13] [14] . Whereas recent studies in mammalian cells have emphasized the role of KMT2D as the major enzyme responsible for H3K4me1 at enhancer regions [20] [21] [22] , KMT2D-deficient alleles in this study were also consistently associated with diminished trimethylation, suggesting a nonredundant role in mature B cells. Accordingly, KMT2D-bound regions in GC B cells display widespread overlap with both H3K4me1 at putative GC enhancers 41, 42 (including predicted superenhancers) 43, 44 and H3K4me3 at gene promoters (Supplementary Notes and Supplementary Fig. 10b,c) , consistent with the requirement of Drosophila Trithorax-related (Trr) in enhancer-promoter communication for faithful and tissue-specific gene expression 45, 46 .
Loss of Kmt2d perturbed the expression of genes that sustain proliferation and survival, and the KMT2D protein directly binds and associates with an active chromatin conformation in negative modulators of the BCR and lymphocyte migration pathways, which in turn could affect B cell responses to antigen. Moreover, KMT2D mapped to 349 out of 593 putative super-enhancers identified in GC B cells, many of which were assigned to master regulators of the GC phenotype on the basis of proximity to the nearest transcriptionally active TSS (Supplementary Notes and data not shown) .
One key observation of this study is that stage-specific deletion of Kmt2d (before or after initiation of the GC reaction) influences the magnitude of the transcriptional and phenotypic changes imposed on this population. We hypothesize that the more robust phenotype observed upon early KMT2D inactivation can be explained by two non-mutually exclusive scenarios. First, in CD19-Cre mice, the longer window of time, and hence the higher number of divisions completed by the cell in the absence of Kmt2d activity before entering the GC reaction, might enable the implementation of chromatin changes, as cell division facilitates the replacement of Kmt2d-dependent H3K4me3-and H3K4me1-modified histones by de novo-synthesized unmodified histone H3 (ref. 47) . In support of this hypothesis, the GEPs of Kmt2d-null GC B cells in which the deletion occurred before or after GC formation were qualitatively similar; moreover, the reduction in global histone methylation was less evident in GC B cells purified from Cγ1-Cre mice as compared to that from CD19-Cre mice (compare Supplementary Fig. 7b and Fig. 2e) . On the other hand, the stage of differentiation or cellular context in which KMT2D is lost may have a specific impact on the target cell by remodeling its epigenetic landscape and potentially skewing cell fate decisions. Regardless of the mechanism, two observations lend support to the role of early stage Kmt2d deletion: (i) immunized CD19-Cre mice exhibit a greater than twofold increase in GC B cells, despite the considerably reduced number of FO B cells, suggesting that Kmt2d-null cells have a higher propensity to enter the GC reaction upon antigen stimulation, and (ii) in human tumors, KMT2D alterations represent early events acquired by a common mutated precursor before divergent evolution and clonal expansion into FL and tFL 7, 8, 11 . By enhancing GC responses, early KMT2D loss will create a larger pool of cells that could serve as targets for additional lesions in this genetically unstable environment [48] [49] [50] [51] . Indeed, GC enlargement has been previously shown to favor lymphomagenesis in several mouse tumor models (such as the Bcl6 knock-in and Blimp1 knockout mouse models) 52, 53 .
In summary, we provide evidence from human genetics, functional studies and mouse models that KMT2D is a bona fide tumor suppressor gene in FL and DLBCL. The mechanism of activity of KMT2D is different from that of classical tumor suppressor genes, as it may allow the selection of cell phenotypes (i.e., GC expansion) and transcriptional programs compatible with transformation driven by other oncogenic lesions, rather than having a direct oncogenic action. Finally, the fact that BCL2 deregulation and KMT2D loss are early events preceding FL or DLBCL transformation suggests that targeting these two lesions may represent a rational strategy to eradicate the putative premalignant precursor. The animal model reported here may thus be useful for the preclinical testing of therapeutic approaches that combine inhibitors to BCL2 and histone methyltransferases or demethylases [54] [55] [56] .
METHODS
Methods and any associated references are available in the online version of the paper. Supplementary Table 5 and were cultured in Iscove's Modified Dulbecco's Medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich), penicillin (100 U/ml) and streptomycin (100 µg/ml), except for OCI-Ly10 and OCI-Ly4, which were cultured in RPMI 1640 medium (Life Technologies) containing 20% human plasma and 55 µM β-mercaptoethanol (Life Technologies). Cell lines were verified for identity by fluorescent in situ hydridization (FISH) analysis or by targeted resequencing of previously reported mutated genes (when applicable), unless purchased from commercial sources. HEK 293T cells were cultured in Dulbecco's Modified Eagle Medium (Life Technologies) with 10% FBS, penicillin (100U/ml) and streptomycin (100 µg/ml). All cell lines were verified to be free from Mycoplasma contamination. Human GC centroblasts, naive B cells and memory B cells were isolated from reactive tonsils as described 57 .
Primary tumor samples. Primary biopsies from 97 newly diagnosed, previously untreated DLBCL patients with known KMT2D genetic status were obtained as part of independent studies and have been described 5, 8 . Samples were studied according to a protocol approved by the Institutional Review Board of Columbia University (Exempt Human Subject Research of anonymized or de-identified existing pathological specimens, under regulatory guideline 45 CFR 46.101(b)(4)).
KMT2D genetic data. For a comprehensive assessment of the KMT2D mutation pattern in DLBCL and tFL (Supplementary Fig. 3 ), data generated in our previous studies 5, 8 were integrated with published information from exome sequencing and/or transcriptome sequencing studies 3, 6, 7 , resulting in a total of 250 DLBCL primary cases, 31 DLBCL cell lines and 71 tFL.
Immunohistochemistry and immunofluorescence analysis of human tissues. DLBCL tissue microarrays (TMA) were constructed according to standard procedures 58 and analyzed for KMT2D expression by IHC using a rabbit polyclonal antibody directed against the C terminus of the KMT2D protein (HPA035977, Sigma-Aldrich) (1:200 dilution). Cases were independently scored by two pathologists (D.D-S. and S.H.) and were considered positive if ≥30% of tumor cells showed KMT2D staining in the nucleus. Double-immunofluorescence analysis of KMT2D and BCL6 was performed on formalin-fixed paraffinembedded (FFPE) material from reactive human tonsils using the abovementioned KMT2D-specific antibody (1:200 dilution) and a mouse monoclonal antibody to BCL6 (1:300 dilution)(clone GI191E/A8, Cell Marque). Detection of KMT2D was obtained using the EnVision System-HRP-Rabbit antibody (Dako) followed by Tyramide Signal Amplification system (PerkinElmer); the secondary antibody for BCL6 was Cy-3 AffiniPure donkey anti-Mouse IgG (H+L) (1:400 dilution) (Jackson ImmunoResearch Laboratories, cat# 715-167-003), as reported 59 .
Generation of pCMV-HA-KMT2D wild-type and mutant expression constructs. The KMT2D full-length ORF (NCBI Reference Sequence: NM_003482.3) was assembled into the pCMV-HA vector (Clontech) by sequential subcloning of six contiguous segments obtained in separate RT-PCR amplification reactions using the PfuTurbo Cx DNA Polymerase (Agilent) and, as template, cDNA from human GC B cells, followed by cloning into the Zero Blunt TOPO PCR vector (Life Technologies). The DLBCL and FL-derived missense mutant alleles and the R4712* truncation mutant were generated from the wild-type pCMV-HA-KMT2D construct using the QuikChange II Site-Directed Mutagenesis Kit (Agilent). All plasmids were verified for integrity by diagnostic restriction enzyme digestions using the SalI, NotI, BglII, SacII, XbaI and MfeI sites, and subjected to Sanger sequencing of the full-length KMT2D coding sequence (CDS).
Transient transfection assays. HEK 293T cells were transiently transfected with equimolar amounts (1 µg/ml) of wild-type and mutant pCMV-HA-KMT2D expression vectors using the polyethylenimine method, following published protocols 60 . Cells were harvested 48 h after transfection and used for protein extraction or for isolation of semipurified HA-KMT2D proteins, as described below.
Protein extraction. Whole cell extracts were obtained from cell lines in the log phase of growth or from purified mouse B cells using NP-40 lysis buffer (150 mM NaCl, 1.0% NP-40, 50 mM Tris-HCl pH 8.0) supplemented with proteinase inhibitor cocktail (Sigma-Aldrich) and 0.5 mM phenylmethanesulfonyl fluoride (PMSF) (Roche), according to previously described protocols 61 . For the analysis of histone modifications, the chromatin pellet was subsequently resuspended in RIPA-coIP buffer (Tris-HCl pH 8.0 50mM, NaCl 200mM, Glycerol 5%, MgCl 2 2.5mM, sodium deoxycholate 0.05%, SDS 0.05%) and mobilized by sonication in a Bioruptor Standard sonication device (Diagenode). Extracts were cleared by centrifugation at 12,000 r.p.m. for 10 min.
RNA extraction, cDNA synthesis and quantitative real-time PCR. Total RNA was extracted from DLBCL cell lines and primary mouse lymphocytes by TRIzol (Life Technologies) and treated with DNAse before cDNA synthesis, which was performed using the SuperScript First-Strand Synthesis System (Life Technologies), according to the manufacturer's instructions. The ABsolute QPCR SYBR green mix (Thermo Scientific) was then used to amplify specific cDNA fragments with the oligonucleotides listed in Supplementary Table 6 , in the 7300 Real Time PCR system (Applied Biosystems). Data were analyzed by the change-in-threshold (2 −∆∆C T ) method 62 , using Actin as a housekeeping reference gene.
Immunoblot analysis. Protein extracts were resolved on NuPAGE Trisacetate 3-8% gels (for KMT2D) or Tris-glycine 4-20% gels (for histone H3) (Life Technologies) and transferred to nitrocellulose membranes (GE Healthcare) according to the manufacturer's instructions. Antibodies used were: rabbit polyclonal anti-KMT2D (designated as KMT2D-1185 in Supplementary  Fig. 2 and Supplementary Table 7) , mouse monoclonal antibody to α-tubulin (clone DM1A, Sigma-Aldrich), rabbit polyclonal anti-H3K4me1 (Abcam, cat#ab8895), anti-H3K4me2 (Active Motif, cat#39142), anti-H3K4me3 (Abcam, cat#ab8580), and rabbit monoclonal anti-Histone H3 (clone D1H2, Cell Signaling Technology). The specificity of the antibodies against H3K4 methylation marks has been documented in previous studies (ENCODE Project: http://genome.ucsc.edu/ENCODE/antibodies.html) (see also http:// www.activemotif.com). For immunoblot analysis of Kmt2d expression in mouse tissues, we used a rabbit polyclonal antibody from Diagenode (C15310100). The detailed list of anti-KMT2D antibodies is provided in Supplementary  Table 7 . Loading of chromatin extracts (typically 0.5-1 µg) was adjusted to ensure comparable amounts of total histone H3, which can vary in different cell lines. Quantitation of signal intensity was obtained in the ImageJ software (http://imagej.nih.gov/ij/) by subtracting the background signal measured above each band from the signal measured in each band; areas of the same size (set on the image of the wild-type protein) were used for all measurements. Values are expressed as fold differences relative to the wild-type protein sample, set at 1, after normalization for the loading control.
In vitro histone methyltransferase (KMT) assay. Partially purified HA-KMT2D wild-type and mutant derivative proteins were obtained from transfected HEK 293T cells by lysis in co-IP buffer (50 mM Tris, pH 7.5, 250 mM NaCl, 1% TritonX-100, 1 mM EDTA), followed by overnight incubation with EZview™ Red Anti-HA Affinity Gel (Sigma-Aldrich) at 4 °C and final elution in BC100 buffer (20 mM Tris pH 7.5, 10% Glycerol, 0.2 mM EDTA, 1% TritonX-100, 100 mM NaCl) containing HA peptide (Sigma-Aldrich). Products were concentrated in the Vivaspin Sample Concentrators (GE Healthcare, 10 kDa cutoff) at 12,000 r.p.m. for 10 min. KMT2D protein amounts were quantified by Coomassie staining and immunoblot analysis using rat monoclonal antibodies to HA (clone 3F10, Roche).
KMT activity against an artificial H3 peptide was assayed using the EpiQuik Histone Methyltransferase Activity-Inhibition Assay Kit (H3K4) (Epigentek), following the manufacturer's protocol. Relative activity was calculated as the fold change in OD 450nm over the mean reading of wild-type samples. Experiments were performed in triplicate and repeated independently at least twice.
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Enzymatic activity against native nucleosomes was measured following a published method 27 . Briefly, equal amounts of wild-type or mutant HA-KMT2D proteins were incubated at 37 °C for 2 h with HeLa nucleosomes (Reaction Biology) in KMT buffer (50 mM Tris pH 8.5, 100 mM KCl, 5 mM MgCl2, 10% glycerol, 4 mM DTT) supplemented with S-adenosyl methionine (New England BioLabs). Reactions were stopped by adding equal volumes of 2× Laemmli buffer and heated at 100 °C for 5 min before loading onto Tris-glycine 4-20% gradient gels. All assays were performed twice independently.
Mice. The conditional Kmt2d knockout mouse model (mixed C57BL/6 × Sv129 background) has been published 21 . Deletion of Kmt2d in GC B cells or in precursor B cells was obtained by breeding Kmt2d fl/+ mice with CD19-Cre 29 or Cγ1-Cre 28 mice (both in pure C57BL/6 background), followed by offspring intercrossing. Compound mice carrying the conditional Kmt2d allele (either CD19-Cre or Cγ1-Cre) and the VavP-Bcl2 transgene were obtained by breeding with VavP-Bcl2 mice (C57BL/6 background) 38 . A sample size of ≥23 animals per genotype was calculated to ensure over 80% power to detect an increase in tumor formation in the Kmt2d compound lines at a P < 0.05 significance. Both females and males were included in the experiment and no randomization was used. Genotyping was performed by PCR analysis using oligonucleotides 5′-ATTGCATCAGGCAAATCAGC-3′ (forward) and 5′-GCA GAAGCCTGCTATGTCCA-3′ (reverse). Animals were monitored for tumor incidence and survival twice a week over a period of 18 months and were killed for analysis when visibly ill or at the end of the study, according to protocols approved by the National Cancer Institute and Columbia University Institutional Animal Care and Use Committee.
Mouse Immunizations. For the analysis of T cell-dependent responses, agematched 8-to 12-week-old mice (males and females) were immunized by intraperitoneal injection of 500 million sheep red blood cells (SRBC) (Cocalico Biologicals) in 200 µl PBS, and were then analyzed after 10 d. Alternatively, mice were immunized with 100 µg 4-hydroxy-3-nitrophenylacetyl hapten conjugated to Keyhole Limpet hemocyanin (NP-KLH) (Biosearch Technologies) along with complete Freund's Adjuvant (Sigma-Aldrich) and analyzed after 12 and 28 days. To achieve a higher yield of GC B cells for gene expression profile analysis, mice were immunized with two sequential SRBC injections (day 0: 1 × 10 8 cells; day 5: 1 × 10 9 cells) and sacrificed at day 12. Mice in the tumor-watch cohort were subjected to chronic immunization by repeated antigenic stimulation with 5 × 10 8 SRBC, delivered every two months until tumor development, death or end of the study.
Flow cytometric analysis.
Multicolor flow cytometric analysis of B and T cell lymphoid compartments was performed at 3 and 6 months of age as previously reported 52 . The B cell compartment was also examined in all animals from the tumor-watch cohort after they were killed. Briefly, single-cell suspensions prepared from various lymphoid organs and from the peritoneal cavity were stained using different combinations of fluorescent-labeled antibodies (listed in Supplementary Table 7) . Samples were acquired on a FACSCanto II (BD Biosciences) and analyzed using the FlowJo software (Tree Star).
Ex vivo stimulation of splenic lymphocytes with CD40-specific antibody and IL4. Splenic mouse B cells were isolated from age-and sex-matched 8-to 12-week-old mice by negative selection using the mouse B cell isolation kit from Miltenyi Biotec, according to the manufacturer's instructions. The purity of the B cell population was 96-98% in all experiments, as documented by flow cytometric analysis of B220 expression. Cells were cultured in RPMI 1640 medium supplemented with 15% FBS, 55 µM β-mercaptoethanol, 1 µg/ml Hamster monoclonal antibody to CD40 (clone HM40-3, BD Pharmingen) and 50 ng/ml recombinant mouse IL4 (R&D Systems).
Cell viability and proliferation assays. The number of viable cells in the ex vivo cultures was determined by measuring the presence of ATP, which signals the presence of metabolically active cells, using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega), as per manufacturer's instructions. Cell proliferation was analyzed with the CellTrace™ Violet Cell Proliferation Kit (Life Technologies), which monitors distinct generations of proliferating cells by dilution of a fluorescent dye. Data were acquired at day 2, 3 and 4 of stimulation on a FACSCanto II (BD Biosciences) flow cytometer with 405-nm excitation and an emission filter in the 450-nm range. All experiments were performed in at least two independent groups of animals, in biological triplicates.
Cell cycle analysis. To assess the cell cycle profiles of Kmt2d fl/fl versus Kmt2d fl/+ and Kmt2d +/+ B cells in the CD19-Cre and Cγ1-Cre cohorts, B220 + splenocytes were labeled with bromodeoxyuridine (BrdU) for 2 h and analyzed for BrdU incorporation and DNA content using the APC BrdU flow kit (BD Biosciences) on a FACSCanto II (BD Biosciences) flow cytometer. Experiments were performed in triplicate at day 3, 4 and 5 after stimulation with CD40-specific antibody and IL4.
GC B cell DNA content analysis. For DNA content analysis, splenic B cell suspensions were stained for surface markers, fixed with Fixation-Permeabilization Solution Kit (BD Biosciences) for 30 min on ice and then incubated with the DNA-binding dye 4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI, Sigma) at the final concentration of 300 ng/ml for 5 min, as described 59 . Samples were acquired at a maximum of 1,500 events per second on a LSR II Flow Cytometer System (BD Biosciences). Cell cycle analysis was performed in the Flow-Jo software (Tree Star). Histological and immunohistochemical analysis of mouse tissues. Histological analysis of mouse organs was performed on 4-µm thick FFPE tissue sections stained with H&E (Thermo Scientific) 53 . The following primary antibodies and dilutions were used for immunohistochemical analysis: rabbit polyclonal anti-Bcl6 (1:300) (N3, Santa Cruz Biotechnology) and anti-Pax5 (1:400) (Neomarker); rabbit monoclonal anti-CD3 (1:800) (clone SP7, Neomarker) and anti-Ki67 (1:200) (clone SP6, Thermo Scientific); rat monoclonal anti-B220 (1:400) (clone RA3-6B2, BD Biosciences) and anti-CD138 (1:200) (clone 281-2, BD Biosciences); mouse monoclonal anti-Bcl2 (1:200) (clone Bcl-2/100, BD Biosciences).
Diagnosis of mouse lymphoid tumors.
Lymphoproliferative diseases developing in the VavP-Bcl2 × Kmt2d Cγ1-Cre cohort were diagnosed independently by two pathologists (D.D.-S. and S.H.) on the basis of morphology and phenotype using the following criteria, in accordance with the classification of human lymphoma: (i) early stages of FL (eFL), as defined by the presence of one or a few oversized, often coalescent, follicles with partial or absent mantle zone and loss of confinement in the context of a yet-preserved tissue architecture; (ii) overt FL of various grades, characterized by effacement of the nodal architecture by a proliferation of follicle center B cells with a follicular growth pattern occupying the medullary and/or paracortical areas; (iii) DLBCL, as defined by the effacement of the lymphoid organ architecture due to the expansion of large cells, with occasional infiltration beyond the capsule into surrounding soft tissues. The genotype of the animal was not disclosed to the pathologists. Immunohistochemical analysis of B220 and CD3, Bcl6, Pax5 and CD138 was performed as described in the previous section.
Southern blot analysis. High-molecular-weight genomic DNA was obtained from frozen tissues by phenol-chloroform extraction, according to standard protocols 63 . Four micrograms of DNA were digested with EcoRI overnight at 37 °C. The digestion reaction was resolved on a 0.8% agarose gel followed by transfer to nitrocellulose membrane, according to standard procedures. Hybridization was performed at 37 °C overnight using a Jh4-specific probe, as reported 49 . npg H3K4me1, H3K4me3 and H3K27Ac, and only peaks identified as significant in both GC B cell pools were considered in the study. Peaks were considered overlapping if they shared at least 1 bp; H3K4me1 (or H3K27Ac) peaks were stitched together into regions if located within ±2 kb (or ±12.5 kb) of distance from each other, unless mapping around the transcription start site (TSS) (±2 kb). H3K27me3 peaks were called using RSEG with 100-bp bin size; only peaks above 5 kb in size were considered. The significance of the overlap between KMT2D-occupied regions and H3K4-methylated regions (or H3K27-acetylated regions) was assessed by binomial tests considering the total size (in bp) of the significant peaks identified in the two ChIP-seq experiments (such as KMT2D versus H3K4me1) and the size of the overlapping region between the two experiments relative to total genome size of the UCSC hg19 assembly.
Definition of active promoters and enhancers. KMT2D-bound regions (peaks) were classified as active promoters if located in close proximity to the TSS of an annotated gene (−2 kb to +1 kb) and enriched in H3K4me3 but not H3K27me3. Intragenic (exonic or intronic) and intergenic regions were considered to be active enhancers if they were located distal to a TSS (greater than ±2 kb) and enriched in H3K4me1 and H3K27Ac but not in H3K4me3 (refs. 41,42,74) . For the identification of super-enhancers in GC B cells, we applied the ROSE algorithm (https://bitbucket.org/young_computation/rose) 43, 75 to our H3K27Ac ChIP-Seq data set. Occupancy of KMT2D at super-enhancers was then determined on the basis of overlap between the KMT2D peaks and the genomic regions identified by ROSE.
Assignment of active enhancers to genes. KMT2D-bound putative active enhancers, identified as described above, were assigned to the nearest expressed and transcriptionally active gene (distance from enhancer center to TSS) as the most likely candidate target gene 44 .
Statistical analyses. P values were calculated by one-way ANOVA with Tukey's multiple comparisons or by the Student's t-test (two-tailed, equal variance) in the GraphPad Prism 5 software. The Fisher's exact test (two-tailed) was used to assess whether differences in the incidence of lymphoproliferative disorders and in the fraction of W33L + V186.2 rearrangements were significant in Kmt2d-null mice as compared to heterozygous and control wild-type littermates. The specific test adopted for parametric and nonparametric analyses is described in each figure legend. Kaplan-Meier event-free survival curves were generated using the GraphPad Prism 5 software (GraphPad Software), and statistical significance was calculated using the log-rank (Mantel-Cox) test. No randomization was used in the study; for the histopathological analysis of human and mouse tissue biopsies, investigators were blinded to sample identity.
